Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.suvenpharm.com | |
Market Cap | 12,506.78 Cr. | |
Enterprise Value(EV) | 12,472.89 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 16.94 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 28.90 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 32.90 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 59.04 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 8.29 | Calculated using Price: 489.75 |
Dividend Yield | 1.02 | Period Ending 2022-03 |
No. of Shares Subscribed | 25.46 Cr. | 254,564,956 Shares |
FaceValue | 1 | |
Company Profile | ||
The company is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry. |
1 Day |
|
+0.15% |
1 Week |
|
-1.05% |
1 Month |
|
-0.09% |
3 Month |
|
+18.97% |
6 Month |
|
+4.20% |
1 Year |
|
-2.94% |
2 Year |
|
+4.41% |
5 Year |
|
|
10 Year |
|
4 years | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 18.92 | 37.80 | 30.47 | 30.48 | |
Return on Capital Employed (%) | 23.87 | 44.55 | 36.19 | 43.13 | |
Return on Assets (%) | 13.39 | 25.50 | 21.52 | 23.30 |
Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 590 | 845 | 1,181 | 1,527 | 1,503 | |
Non Curr. Liab. | 35 | 128 | 74 | 92 | 86 | |
Curr. Liab. | 191 | 320 | 322 | 348 | 216 | |
Minority Int. | ||||||
Equity & Liab. | 816 | 1,292 | 1,576 | 1,967 | 1,806 | |
Non Curr. Assets | 393 | 781 | 910 | 702 | 884 | |
Curr. Assets | 423 | 511 | 667 | 1,265 | 923 | |
Misc. Exp. not W/O | ||||||
Total Assets | 816 | 1,292 | 1,576 | 1,967 | 1,806 |
Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 378 | 834 | 1,010 | 1,320 | 1,373 | |
Other Income | 1 | 18 | 14 | 92 | 104 | |
Total Income | 378 | 852 | 1,024 | 1,413 | 1,476 | |
Total Expenditure | -206 | -449 | -567 | -739 | -779 | |
PBIDT | 172 | 403 | 457 | 674 | 697 | |
Interest | -3 | -23 | -12 | -9 | -5 | |
Depreciation | -12 | -24 | -32 | -39 | -44 | |
Taxation | -49 | -88 | -105 | -214 | -217 | |
Exceptional Items | ||||||
PAT | 109 | 269 | 309 | 413 | 431 | |
Minority Interest | ||||||
Share Associate | 48 | 54 | 41 | |||
Other Related Items | ||||||
Consolidated Net Profit | 109 | 317 | 362 | 454 | 431 | |
Adjusted EPS | 12 | 14 | 18 | 17 |
Particulars | 4 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 50 | 407 | 383 | 330 | |
Cash Fr. Inv. | -65 | -413 | -311 | -136 | |
Cash Fr. Finan. | 26 | 7 | -76 | -156 | |
Net Change | 11 | 1 | -5 | 37 | |
Cash & Cash Eqvt | 11 | 12 | 7 | 45 |
Mon, 16 Jan 2023
Announcement under Regulation 30 (LODR)-Credit Rating Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to intimate you that the CRISIL has assigned the following ratings to the Bank facilities of our Company as per communication received on January 16 2023.Facilities RatingLong-term Bank Facilities CRISIL A+/Watch Developing (Placed on Rating Watch with Developing Implications)Short-term Bank Facilities CRISIL A1+/Watch Developing (Placed on Rating Watch with Developing Implications)This is for your information and record. |
Mon, 09 Jan 2023
Draft Letter of Offer Kotak Mahindra Capital Company Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Draft Letter of Offer for the attention of the public shareholders of Suven Pharmaceuticals Ltd ("Target Company"). |
Fri, 06 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 please find enclosed herewith the Confirmation Certificates issued by KFin Technologies Limited Registrar and Share Transfer Agents of the Company for the quarter ended December 31 2022.This is for your information and record. |
Fri, 27 Jan 2023 |
|
|
|
|
|